What is your top priority for next year?
With a digital-first focus, India Inc’s top bosses are gearing up for an action-packed 2021
Krishna Gopalan - December 04, 2020
What does Rakesh Jhunjhunwala see in Jubilant Life Sciences?
Within a year, the investing legend has doubled down on his latest pharma bet
Himanshu Kakkar - May 23, 2020
New growth model
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Kripa Mahalingam - July 26, 2019
Tricky Transition
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
N Mahalakshmi - July 16, 2019
Growth Inhibitor
In Ankleshwar, feisty MSMEs that survived the Chinese onslaught say that the fight against red tapism is harder
Krishna Gopalan - January 25, 2019
Injecting Growth
By focusing on its strength in manufacturing lyophilized injectables, Gufic Biosciences has made a strong comeback and wants to aggressively push into the EU market next
Jash Kriplani - April 16, 2018
Nursing Back to Health
A strong product pipeline and receding US FDA threat could well turn the tide in favour of the beleaguered pharma players
Jash Kriplani - October 18, 2017
The Comeback Plan
Lupin is betting on its specialty drugs business to counter the pricing pressures in the US generics market
Khushboo Balani - October 03, 2017
Ajay Relan
His bet on Natco Pharma’s differentiated product portfolio paid off while Monnet Ispat taught him to be wary of over-ambitious entrepreneurs
Krishna Gopalan - September 18, 2017
Going all-in
Why Star paid top dollar for India's premier domestic tourney
N Mahalakshmi - September 29, 2017
